Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial
The Journal of Infectious Diseases · 2024
DOI: 10.1093/infdis/jiad546 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Tino F Schwarz und 19 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Laboratory Medicine and Vaccination Centre, Klinikum Würzburg Mitte, Germany. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus Infections, Antibodies, Viral, Respiratory Syncytial Virus, Human. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Background
The recently approved AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein–based vaccine for older adults (RSVPreF3 OA) demonstrated high efficacy against RSV-related disease in ≥60-year-olds.
Methods
This ongoing phase 3 study in ≥60-year-olds evaluates immune persistence until 3 years after RSVPreF3 OA vaccination. Here, we describe interim results on humoral and cell-mediated immunogenicity, reactogenicity, and safety until 1 year post–dose 1.
Results
In total, 1653 participants were vaccinated. One month post–dose 1, neutralization titers increased 10.5-fold (RSV-A) and 7.8-fold (RSV-B) vs pre–dose 1. Titers then declined to levels 4.4-fold (RSV-A) and 3.5-fold (RSV-B) above pre–dose 1 at month 6 and remained 3.1-fold (RSV-A) and 2.3-fold (RSV-B) above pre–dose 1 levels after 1 year. RSVPreF3-binding immunoglobulin G levels and CD4+ T-cell frequencies showed similar kinetics. Solicited administration-site and systemic adverse events (mostly mild to moderate and transient) were reported by 62.2% and 49.5% of participants. Serious adverse events were reported by 3.9% of participants within 6 months post–dose 1; 1 case was considered vaccine related.
Conclusions
One RSVPreF3 OA dose elicited cell-mediated and RSV-A– and RSV-B–specific humoral immune responses that declined over time but remained above pre–dose 1 levels for at least 1 year. The vaccine was well tolerated with an acceptable safety profile. Clinical Trials Registration. NCT04732871 (ClinicalTrials.gov).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Laboratory Medicine and Vaccination Centre, Klinikum Würzburg Mitte, Germany.
- En Chu Kong Hospital, New Taipei City, and Taipei Veterans General Hospital and School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Alliance for Multispecialty Research, Fort Myers, Florida.
- China Medical University and China Medical University Hospital, Taichung, Taiwan.
- Medical Corporation Shinanokai, Shinanozaka Clinic, Tokyo, Japan.
- Nishi-Kumamoto Hospital, Kumamoto, Japan.
Zitieren
APA
Schwarz, T. F., Hwang, S. J., Ylisastigui, P., Liu, C. S., Takazawa, K., Yono, M., Ervin, J. E., Andrews, C. P., Fogarty, C., Eckermann, T., Collete, D., de Heusch, M., De Schrevel, N., Salaun, B., Lambert, A., Maréchal, C., Olivier, A., Nakanwagi, P., Lievens, M., & Hulstrøm, V. (2024). Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad546
Vancouver
Schwarz TF, Hwang SJ, Ylisastigui P, Liu CS, Takazawa K, Yono M, et al. Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiad546
BibTeX
@article{Schwarz2024,
author = {Schwarz, Tino F and Hwang, Shinn-Jang and Ylisastigui, Pedro and Liu, Chiu-Shong and Takazawa, Kenji and Yono, Makoto and Ervin, John E and Andrews, Charles P and Fogarty, Charles and Eckermann, Tamara and Collete, Delphine and de Heusch, Magali and De Schrevel, Nathalie and Salaun, Bruno and Lambert, Axel and Maréchal, Céline and Olivier, Aurélie and Nakanwagi, Phoebe and Lievens, Marc and Hulstrøm, Veronica},
title = {Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiad546}
}
EUVIMED